PolyPid (PolyPid) Minority Interest : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is PolyPid Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

PolyPid's minority interest for the quarter that ended in Mar. 2024 was $0.00 Mil.

PolyPid Minority Interest Historical Data

The historical data trend for PolyPid's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPid Minority Interest Chart

PolyPid Annual Data

Trend

Dec12

Dec13

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Minority Interest

Get a 7-Day Free Trial

PolyPid Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Minority Interest	Get a 7-Day Free Trial															-	-	-	-	-

PolyPid Minority Interest Calculation

PolyPid (PolyPid) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PolyPid Ltd (NAS:PYPD) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Hasivim Street, P.O Box 7126, Petach Tikva, ISR, 495376

Website

https://www.polypid.com

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, and Bacyssio are trademarks of the company. The company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.